An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder

• Status: Completed
• Trial end date: 2004-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Diagnosis of Major Depressive Disorder (MDD)

• Duration of current depressive episode 12 weeks - 24 months

• Patients can read and write at a level sufficient to provide a signed consent

• If female, patients must be practicing an acceptable method of birth control

Exclusion Criteria:

• Patients have other psychiatric disorders that would affect patient's response to treatment

• Patients have not responded to two or more adequate courses of antidepressant therapy

• Patients cannot be currently abusing illicit drugs or alcohol

• Patients are not currently receiving psychotherapy

• Patients have received electroconvulsive therapy within 6 months prior to screening

• Patients are pregnant or lactating